Cargando…
Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma
Hemangioblastoma (HB) is a rare, highly vascularized, and benign central nervous system (CNS) tumor. This vascularity is due to a high degree of signaling by vascular endothelial growth factor (VEGF). Consequently, anti-VEGF agents, such as bevacizumab, have been postulated and shown in a few cases...
Autores principales: | Sokol, Zachary, Hoeft, Ava, Kung, David, Belman, Neil, Oselkin, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841884/ https://www.ncbi.nlm.nih.gov/pubmed/36654589 http://dx.doi.org/10.7759/cureus.32624 |
Ejemplares similares
-
Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab
por: Francis, Jasmine H., et al.
Publicado: (2018) -
Recurrent hemorrhage in hemangioblastoma involving the posterior fossa: Case report
por: Marvin, Eric, et al.
Publicado: (2017) -
A solitary hemangioblastoma of the posterior brain fossa: the role of radiotherapy
por: Abboud, Fatima Zahra, et al.
Publicado: (2020) -
Normalization of systemic arterial hypertension following removal of posterior fossa hemangioblastoma: a case report
por: Saberi, Hooshang, et al.
Publicado: (2009) -
A Multidisciplinary Approach in the Management of a Paediatric Posterior Fossa Ischaemic Stroke: A Case Report
por: Buonomo, Orazio, et al.
Publicado: (2019)